Biology and treatment of chronic lymphocytic leukemia

被引：15
作者：
Kokhaei, P [4 ]
Palma, A
Mellstedt, H
Choudhury, A
机构：
[1] Karolinska Univ Hosp, Canc Ctr Karolinska, Immune & Gene Therapy Lab, Stockholm, Sweden
[2] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden
[3] Karolinska Univ Hosp, Canc Ctr Karolinska, Immune & Gene Therapy Lab, Stockholm, Sweden
[4] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
10.1093/annonc/mdi731
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：113 / 123
页数：11
相关论文
共 92 条
[1]   An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia [J].
Alfarano, A ;
Indraccolo, S ;
Circosta, P ;
Minuzzo, S ;
Vallario, A ;
Zamarchi, R ;
Fregonese, A ;
Calderazzo, F ;
Faldella, A ;
Aragno, M ;
Camaschella, C ;
Amadori, A ;
Caligaris-Cappio, F .
BLOOD, 1999, 93 (07) :2327-2335
[2]  
BINET JL, 1990, BRIT J HAEMATOL, V76, P45
[3]  
BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
[4]  
2-V
[5]   Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia [J].
Bosch, F ;
Ferrer, A ;
López-Guillermo, A ;
Giné, E ;
Bellosillo, B ;
Villamor, N ;
Colomer, D ;
Cobo, F ;
Perales, M ;
Esteve, J ;
Altés, A ;
Besalduch, J ;
Ribera, JM ;
Montserrat, E .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (04) :976-984
[6]   Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].
Byrd, JC ;
Peterson, BL ;
Morrison, VA ;
Park, K ;
Jacobson, R ;
Hoke, E ;
Vardiman, JW ;
Rai, K ;
Schiffer, CA ;
Larson, RA .
BLOOD, 2003, 101 (01) :6-14
[7]   A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211 [J].
Byrd, JC ;
Peterson, B ;
Piro, L ;
Saven, A ;
Vardiman, JW ;
Larson, RA ;
Schiffer, C .
LEUKEMIA, 2003, 17 (02) :323-327
[8]   Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity [J].
Byrd, JC ;
Murphy, T ;
Howard, RS ;
Lucas, MS ;
Goodrich, A ;
Park, K ;
Pearson, M ;
Waselenko, JK ;
Ling, G ;
Grever, MR ;
Grillo-Lopez, AJ ;
Rosenberg, J ;
Kunkel, L ;
Flinn, IW .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2153-2164
[9]  
Byrd John C, 2004, Hematology Am Soc Hematol Educ Program, P163
[10]   Role of the microenvironment in chronic lymphocytic leukaemia [J].
Caligaris-Cappio, F .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (03) :380-388
12345678910